The North American Menopause Society has released a new position statement on the screening, prevention, diagnosis and treatment of osteoporosis in postmenopausal women. (Menopause)
The FDA approved lonapegsomatropin-tcgd (Skytrofa) for the treatment of pediatric patients who weigh at least 11.5 kg and who have growth retardation due to insufficient secretion of endogenous growth hormone, Ascendis Pharma announced. The once-weekly injection is the first approved treatment to deliver somatropin by sustained release over the course of the week.
Due to payer contracts and the type of insurance, Lantus could still be the cheaper option for some patients with diabetes compared to Semglee insulin glargine – just approved as the first interchangeable biosimilar insulin – despite Semglee being about 64% cheaper than Lantus based on US wholesale costs (GlobalData)
The endocrine self-assessment program In-Training Examination is highly predictive of results from the American Board of Internal Medicine-Endocrinology, Diabetes and Metabolism Certification Examination, a new study found. (Journal of the Endocrine Society)
Building on a recent report, the FDA has released the latest set of results for quantifying per- and polyfluoroalkyl substances (PFAS) in nationally distributed processed foods. All in all, 164 of the 167 foods tested had no detectable levels of PFAS, and the only foods that showed contamination were fish fingers, canned tuna and protein powder.
The Endocrine Society has announced it has established a new executive-level position focused on membership and diversity, which will first be filled by Rodneikka Scott, MSc, CAE.
According to a group of international researchers in a new consensus report published in the Journal of Clinical Endocrinology and Metabolism.
During the first wave of COVID-19 in England, hospital admissions for diabetic ketoacidosis fell for patients with type 1 diabetes, but rose for those with type 2 diabetes and those newly diagnosed with diabetes. (The Lancet Diabetes & Endocrinology)
The FDA has announced the first and only treatment for pruritus associated with chronic kidney disease in adults undergoing hemodialysis: difelikephaline (Korsuva), Cara Therapeutics and Vifor Pharma.
Kristen Monaco is a staff writer focusing on news in endocrinology, psychiatry and dermatology. She works out of the New York City office and has been with the company for nearly five years.